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1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; 2Department of
Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands; 3Department of
Oncology, National Taiwan University Hospital, Taipei City, Taiwan; 4University of Waterloo, Toronto, ON, Canada; 5Division of Medical
Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada and 6Canadian Centre for Applied Research in Cancer Control,
Toronto, ON, Canada
Background: The majority of published studies in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are single-arm
trials. Reliable modelling of progression-free survival (PFS) and overall survival (OS) outcomes, therefore, is difficult. This study aim
to analyse existent literature to estimate the relative efficacy of available systemic regimens in RM-NPC, as well as provide
estimates of aggregate OS and PFS.
Methods: We conducted a systematic search of MEDLINE, EMBASE and the Cochrane Library to March 2015. Clinical trials (in
English only) investigating cytotoxic and molecularly targeted agents in adult patients with RM-NPC were included. All relevant
studies were assessed for quality using Downs and Blacks (DB) checklist (maximum quality score of 27). Aggregate data analysis
and Student’s t-test were performed for all identified studies (model A). For studies that published analysable KaplanMeier
curves, survival data were extracted and marginal proportional hazards models were constructed (model B).
Results: A total of 56 studies were identified and included in model A, 26 of which had analysable KaplanMeier curves and were
included in model B. The 26 studies in model B had significantly higher mean DB scores than the remaining 30 (17.3 vs 13.7,
P¼ 0.002). For patients receiving first line chemotherapy, the estimated median OS was 15.7 months by model A (95% CI,
12.3–19.1), and 19.3 months by model B (95% CI, 17.6–21.1). For patients undergoing second line or higher therapies (2ndþ ), the
estimated median OS was 11.5 months by model A (95% CI 10.1–12.9), and 12.5 months by model B (95% CI 11.9–13.4). PFS
estimates for patients undergoing first-line chemotherapy by model A was 7.6 months (95% CI, 6.2–9.0), and 8.0 months by model
B (95% CI, 7.6–8.8). For patients undergoing therapy in the 2ndþ setting, the estimated PFS by model A was 5.4 months (95% CI,
3.8–7.0), and 5.2 months by model B (95% CI, 4.7–5.6).
Conclusions: We present the first aggregate estimates of OS and PFS for RM-NPC patients receiving first and second-line or
higher treatment settings, which could inform the design of future clinical trials in this disease setting.
On a global scale, nasopharyngeal carcinoma (NPC) causes
B65 000 deaths annually, although its incidence varies widely by
region (Ferlay et al, 2010). While rare in North America and
Europe, the incidence of NPC exceeds 20 cases per 100 000 people
in endemic regions, such as Southern China, Southeast Asia and
the Middle East/North Africa (Chang and Adami, 2006). Different
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factors are thought to contribute to the pathogenesis of cases in
endemic and non-endemic regions. EpsteinBarr virus (EBV)
infection, environmental factors and genetic predisposition are
proposed to be the main contributing factors in endemic regions,
while the classic risk factors for other head and neck tumors such
as smoking, alcohol and human papilloma virus (HPV) infection
are thought to account more for cases in non-endemic areas
(Vaughan et al, 1996; Chua et al, 2016).
Approximately 5 11% of patients present with de novo
metastatic disease, while a further 15 30% of patients who were
treated for locally advanced NPC will develop local recurrence and/
or distant metastatic disease (Lee et al, 2015). Most recurrent cases
are not amenable to salvage therapy with surgery and/or radio-
therapy with or without concurrent chemotherapy. Hence,
treatment options for the majority of patients with recurrent or
metastatic NPC (RM-NPC) are largely limited to palliative
systemic therapies (Lee et al, 2015).
NPC is a chemosensitive disease with some studies reporting
response rates of over 80% with platinum-based chemotherapy
regimens in recurrent or metastatic settings (Leong et al, 2008;
Chen et al, 2013). Durable responses and prolonged survival have
been observed in a subset of patients (de Graeff et al, 1987; Siu
et al, 1998; Taamma et al, 1999). Therefore, despite the lack of
direct comparison to supportive care, systemic chemotherapy is
presently the mainstay of treatment for patients with RM-NPC.
Due to the relatively low disease incidence, clinical trials
investigating systemic therapies for RM-NPC typically enroll a
heterogeneous patient population in a single treatment arm, which
makes modelling of historical patient outcomes difficult (Lee et al,
2015).
This systematic review qualitatively examined studies of
systemic therapies in RM-NPC to determine the relative efficacies
of available drug regimens, and provide estimates of aggregated
progression-free survival (PFS) and overall survival (OS); In
particular, we seek to compare platinum to non-platinum regimens
and investigate aggregate survival outcomes in the second line and
beyond treatment setting. Trends over time in overall response
rates (ORR), PFS and OS were also investigated. The Downs and
Blacks (DB) checklist was chosen to assess the methodological
quality of identified clinical trials as it allows assessment of both
randomised and non-randomised studies (Downs and Black,
1998). Analysis of the association between clinical trial outcomes
(ORR, PFS and OS) and characteristics of the study, including
region where it was conducted, number of patients involved, study
DB score and the year the trial was performed.
MATERIALS AND METHODS
Search strategy. A systematic search of MEDLINE (from 1950),
EMBASE (from 1980), and the Cochrane Library was conducted to
March 2015. Clinical trials investigating cytotoxic and molecularly
targeted agents in adult patients with RM-NPC were included. The
search was limited to human trials and studies published in the
English language. Dose escalation or phase I clinical trials, immune
therapies, concomitant and/or sequential use of radiotherapy or
surgery, curative-intent systemic therapies, trials of patients with
non-NPC histology where patient outcomes were not reported
separately, conference proceedings and abstracts were excluded.
The same search inclusion and exclusion criteria were applied to
studies in models A and B; however, only studies with analysable
KaplanMeier curves were used in model B analysis.
All search results were initially screened for relevance on the
basis of article titles and abstracts by two authors (AP and AH).
Full text articles were then retrieved for shortlisted studies.
Additional trials were identified through manual searches of
reference lists from the included articles. Reviewers were not
blinded to study authors or outcomes. The decision to include a
study for review was made by consensus between two authors (AP
and AH). Disagreements would be resolved by a third author, but
there were no unresolved differences.
Data extraction. Data were extracted by two teams of two
reviewers (AP with AH and SO with TC). The following data were
extracted for each trial: (1) study characteristics including clinical
phase, region conducted and number of patients involved; (2)
reported outcomes including ORR, PFS and OS; (3) grade 3 and 4
toxicities affecting at least 25% of study population; (4) patient
characteristics including age, gender, prior treatment in the
metastatic setting; and (5) details of the systemic therapy regimen
under investigation.
Literature search
Databases: Medline, EMBASE, Cochrane Library
Articles published between January 1950 and February 2015
Electronic database search results
(n = 2971)
Results screened on the basis of titles and
abstracts
Excluded (n = 2903):
• Duplicates (n = 485)
• Non-english (n = 339)
• Review article and abstracts (n = 595)
• Pediatric (n = 110)
• Unrelated to topic (n = 1374)
Full text articles retrieved (n = 68)
Additional articles from manual reference 
search* (n = 2)
Articles assessed against 
inclusion/exclusion criteria (n = 70)
Excluded  (n = 14):
• Conference abstract (n = 2)
• Inclusion of patients with non-NPC
histologies, and results not
reported separately (n = 8)
• Dose escalation study (n = 2)
• Review paper (n = 1)
• Combined analysis of multiple
treatment regimens (n = 1)
Articles included in analysis A (n = 56)
Kaplan–Meier curves not analyzable (n = 30)
Articles included in analysis B (n = 26)
Figure 1. PRISMA flow diagram.
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Au, 1994 Asia 24 Cisplatin 33.3mgm 2 on days 1–3; 5-
fluorouracil 1000mgm 2 daily on
days 1–5, every 3 weeks.
66 8 11 8
Au and Ang,
1998
Asia 24 Paclitaxel 175mgm 2 every 3 weeks. 22 2.5 12 14
Chen et al,
2013
Asia 95 Paclitaxel 135mgm 2 on day 1,
cisplatin 25mgm 2 per day on days
1–3, 5-fluorouracil continuous infusion
over 120 h, 600–1000mgm 2 per
day, every 3 weeks. Maximum of 6
cycles.
78.9 8.6 22.7 18
Chua and
Au, 2005
Asia 19 Docetaxel 75mgm 2 on day 1,
cisplatin 75mgm 2 on day 1, every 3
weeks. Protocol was later modified to
60mgm 2 for both agents.
63 5.6 12.4 23
Chua et al,
2012
Asia 39 Cisplatin 100mgm 2 on day 1,
capecitabine 1000mgm 2 twice daily
for 14 days, every 3 weeks. Maximum
of 6–8 cycles (8 if PR or CR).
54 8.5 28 20
Ciuleanu
et al, 2004
Europe 40 Paclitaxel 175mgm 2, carboplatin
AUC 6, every 3 weeks.
28 3.5 11.5 15
de Graeff
et al, 1987
Europe 4 Doxorubicin 50mgm 2 every 3
weeks, CCNU 120mgm 2 every 6
weeks.
80 Not reported Not reported 9
Fountzillas
et al, 1997
Europe 14 Paclitaxel 200mgm 2, carboplatin
AUC 7, every 4 weeks, with G-CSF.
57 16.5 Not reached 13
Hasbini et al,
1999
Europe 44 5FU 800mgmc 2 on days 1–4,
epirubicin 70mgm 2 on day 1,
cisplatin 100mgm 2 on day 1, every 4
weeks. Mitomycin C 10mgm 2 on
cycle 1 day 1, cycle 3day 1, and cycle
5 day 1. Maximum of 6 cycles.
52 9 14 16
Hsieh et al,
2013
Asia 22 Cisplatin 50mgm 2 on days 1 and 22,
mitomycin C 6mgm 2 on day 1, oral
tegafur-uracil 300mgm 2 day on days
1–14, oral leucovorin 60mg per day on
days 22–35, every 6 weeks.
59 10 16 13
Jelic et al,
1997
Europe 80 Arm A: Zorubicin 325mgm 2 per 24h
on day 1; Arm B: Zorubicin
250mgm 2/24 h on day 1 and
Cisplatin 30mgm 2 per 24 h on days
2–5. All repeated every 4 weeks.
A¼ 20; B¼ 67.5 Not reported Not reported 15
Ji et al, 2012 Asia 46 Docetaxel 35mgm 2 on days 1 and 8,
Cisplatin 70mgm 2 on day 1, every 3
weeks.
70.2 9.6 28.5 25
Leong et al,
2005
Asia 32 Paclitaxel 70mgm 2 on days 1 and 8,
carboplatin AUC 5 on day 1,
gemcitabine 1000mgm 2 on days 1
and 8, every 3 weeks until 2 cycles
beyond maximum response, maximum
total of 8 cycles.
78 8.1 18.6 18
Leong et al,
2008
Asia 28 Gemitabine 1000mgm 2, paclitaxel
70mgm 2, carboplatin AUC 2.5, on
days 1 and 8, every 3 weeks, until 2
cycles beyond maximum response,
maximum total of 6 cycles.
If PR or CR then continue with weekly
5FU 450mgm 2 and Leucovorin
30mgm 2, until PD or maximum
treatment duration of 48 weeks.
86 8 22 21
Li et al, 2008 Asia 48 Capecitabine 1000mgm 2 on days
1–14, cisplatin 80mgm 2 on day 1,
every 3 weeks. Maximum of 6 cycles.
63 7.7 13.5 16
Ma et al,
2009
Asia 40 Gemcitabine 1000mgm 2 on day 1,
oxaliplatin 100mgm 2 on day 2,
every 2 weeks. Maximum of 12 cycles.
56 9 19.6 18
McCarthy
et al, 2002
North America 9 Docetaxel 75mgm 2 on day 1,
cisplatin 75mgm 2 on day 1, every 3
weeks.
22 8.4 1-year survival
rate 76%
19
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North America 90 Schedule 1A: Cyclophosphamide
250mgm 2, doxorubicin 25mgm 2,
cisplatin 50mgm 2, methotrexate
50mgm 2, bleomycin 15mgm 2,
every 4 weeks.
Schedule 1B: Cyclophosphamide
200mgm 2, doxorubicin 20mgm 2,
cisplatin 50mgm 2, methotrexate
50mgm 2, bleomycin 10mgm 2,
folinic Acid 10mg every 6 h for 4
doses, every 4 weeks.
Schedule 2A: Cyclophosphamide
350mgm 2, doxorubicin 35mgm 2,
cisplatin 70gm 2, methotrexate
50mgm 2, bleomycin 15mgm 2,
every 4 weeks.
Schedule 2B: Cyclophosphamide
350mgm 2, doxorubicin 35mgm 2,
cisplatin 70mgm 2, methotrexate
50mgm 2, bleomycin 10mgm 2,
folinic Acid 10mg every 6 h for 4
doses, every 3 weeks.
All patients 73;
VALD 86; MLD 41;
MMD 80.






Africa 18 Cisplatin 50mgm 2 and ifosfamide
3gm 2 on days 1–2, every 3–4 weeks.
59 6.5 13.6 10
Tan et al,
1999
Asia 32 Paclitaxel 175mgm 2 and carboplatin
AUC 6, every 3 weeks.






Asia 24 Mitoxantrone 12–4mgm 2, every 3
weeks.
38 4.4 5.3 10
Xue et al,
2013
Asia 54 Sorafenib 400mg twice daily, cisplatin
80mgm 2 on day 1, 5-fluorouracil
1000mgm 2 per day continuous
infusion for 4 days, every 3 weeks to a
maximum of 6 cycles, then followed by
maintenance sorafenib.
78 7.2 11.8 20
You et al,
2012
North America 19 Gemcitabine 1000mgm 2 on days 1
and 8, cisplatin 70mgm 2 or
Carboplatin AUC 5 on day 1, every 3
weeks. Then switch to Erlotinib 150mg











Europe 12 Carboplatin AUC 5.5, paclitaxel
175mgm 2, every 3 weeks.
25 10 9.5 10
Altundag
et al, 2004
Asia 21 Ifosfamide 2500mgm 2 on days 1–3,
mesna 2500mgm 2 on days 1–3,
doxorubicin 60mgm 2 on day 1,
every 3 weeks.
33.5 7 Not reported 9
Chan et al,
2005
Mixed 60 Cetuximab 400mgm 2 then
250mgm 2 weekly, carboplatin AUC
5, every 3 weeks to a maximum of 8
cycles.
11.7 2.7 7.7 16
Chen et al,
2012
Asia 56 Vinorelbine 25mgm 2 and
gemcitabine 1000mgm 2 on days 1
and 8, every 3 weeks.
37.7 5.2 14.1 23
Chua and
Au, 2003
Asia 17 Capecitabine 1.25gm 2 twice daily
for 2-weeks, every 3 weeks.
23.5 4.9 7.6 18
Chua et al,
2008
Asia 49 Capecitabine 1–1 25gm 2 twice
daily for 2-weeks, every 3 weeks.
37 5 14 12
Ciuleanu
et al, 2008
Europe 23 Capecitabine 2500mgm 2 per day
for 14 days, every 3 weeks, to a
maximum of 6 cycles.





Europe 20 5-fluorouracil continuous infusion
300mgm 2 per day until PD.
25 4 10 10
Lim et al,
2011
Asia 33 Pazopanib 800mg daily. 6.1 4.4 10.8 23
Ma et al,
2008
Asia 15 Gefitinib 500mg per day every 4
weeks. Maximum treatment duration
of 8 months.
0 2.7 12 18
Peng et al,
2013
Asia 45 Capecitabine 1000mgm 2 on days
1–14, Nedaplatin IV 8-mgm 2 on day
1, every 3 weeks.
41.7 5.8 12.4 16
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Asia 28 Irinotecan 100mgm 2, weekly for 3
weeks, every 4 weeks.
14 3.9 11.4 23
Wang et al,
2006
Asia 35 Vinorelbine 20mgm 2, gemcitabine
1000mgm 2, on days 1 and 8, every
3 weeks.
36 5.6 11.9 21
Zhang et al,
2008
Asia 30 Gemcitabine 1000mgm 2 on days 1,
8 and 15, every 3 weeks.
43.8 5.1 16 15
Zhang et al,
2012
Asia 35 Pemetrexed 500mgm 2 every 3
weeks.
2.9 1.5 13.3 14
Mixed first-line and 2ndþ treatment settings
Azli et al,
1995
Europe 44 Cisplatin 100mgm 2 on day 1,
epirubicin 80mgm 2 on day 1,
bleomycin 15mgm 2 bolus on day 1,
bleomycin continuous infusion
16mgm 2 per day on days 1–5, every
3 weeks for 3 cycles; Followed by 3
further cycles without bleomycin, total
maximum of 6 cycles.
20 Not reported Not reported 10
Boussen
et al, 1991
Europe 49 Cisplatin 100mgm 2 on day 1,
bleomycin 15mg on day 1 and
16mgm 2 per day continuous
infusion on days 1–5, 5-fluorouracil
650mgm 2 per day on days 1–5,
every 4 weeks, to a maximum of 3
cycles.
79 Not reported Not reported 11
Chan et al,
1998
Asia 14 Temozolomide 150mgm 2 daily for 5
days, every 4 weeks. If previous
chemotherapy, 150mgm 2; if
treatment naive 200mgm 2.
0 Not reported Not reported 17
Chua et al,
2000
Asia 18 Ifosfamide 1.2 gm 2, leucovorin
20mgm 2, 5-fluorouracil
375mgm 2, all on days 1–5 with
mesna, every 3 weeks.





Asia 19 Gefitinib 250mg daily, continuous. 0 4 16 21
Dugan et al,
1993
Asia 99 Mitoxantrone 12mgm 2 every 3
weeks.







Gemcitabine 1250mgm 2 on days 1

















Asia 44 Gemcitabine 1000mgm 2 on days 1
and 8, cisplatin 50mgm 2 no days 1
and 8, every 4 weeks.
73 10 6 15 15
Lin and Hsu,
1998
Asia 44 Cisplatin 25mgm 2, 5-fluorouracil
1250mgm 2 by continuous infusion
over 24 h, weekly to a maximum of 24
cycles.
Dose escalated after 19 patients to:
Cisplatin 33.3mgm 2 and 5-
fluorouracil 1667mgm 2.
52.7 CR 6.5; PR 5.5 9 14
Ma et al,
2002
North America 32 Gemcitabine 1000mgm 2 on days 1,
8 and 15, with or without cisplatin
70mgm 2 on day 2, every 28 days.







Asia 30 Docetaxel 30mgm 2 on days 1, 8 and
15, every 4 weeks.
37 5.3 12.8 17
Su et al,
1993
Asia 25 Cisplatin 20mgm 2 per day on days
1–5, 5-fluorouracil 1000mgm 2 per
day on days 1–5, bleomycin
15mgm 2 on day 1, every 3–4 weeks.
40 Not reported Not reported 8
Wang et al,
2008
Asia 75 Gemcitabine 1000mgm 2 on days 1
and 8, cisplatin 25mgm 2 on days 1–
3, every 3 weeks.
42.7 5.6 9 14
Yau et al,
2012
Asia 15 Pemetrexed 500mgm 2, cisplatin
75mgm 2, every 3 weeks.
20 6.9 Not reported 11
Yeo et al,
1996
Asia 42 Carboplatin 300mgm 2 on day 1, 5 F-
fluorouracil 1 gm 2 per day on days
1–3, every 3 weeks to a maximum of 8
cycles.
38 Not reported 12.1 16
Yeo et al,
1998
Asia 27 Carboplatin AUC 6, paclitaxel
135mgm 2, every 3 weeks to a
maximum of 6 cycles.
59 6 13.9 15
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Data analysis. All relevant studies were assessed for quality using
the DB checklist (Downs and Black, 1998), which provided an
overall score indicating reporting quality, internal validity (bias and
confounding), power and external validity (Downs and Black,
1998). Aggregated data analysis and Student’s t-tests were
performed for all identified studies (model A). Two-sided P-values
were calculated with a cutoff of 0  05 for significance. For studies
that published KaplanMeier (KM) curves with sufficient
resolution and details regarding censoring, survival data were
extracted from the KM curves using electronic software, DigitizeIt,
Germany, and individual patient-level data were recreated (Guyot
et al, 2012). Survival analysis with marginal proportional hazard
model methods was used to account for the clustering of patients
within trials (model B) (Lin, 1994).
Response rate analyses were performed for all identified studies
in model A. To account for clustering of data within studies, a














Number of prior treatment lines not described
Dede et al,
2012
Asia 30 Ifosfamide 2500mgm 2 on days 1–3,
mesna 2500mgm 2 on days 1–3,
doxorubicin 60mgm 2 on day 1,
every 3 weeks to a maximum of 6
cycles.
30 4 Not reported 9
Taamma
et al, 1999
Europe 26.  23
evaluable for
response
5FU 700mgm 2 per day on days 1–4,
epirubicin 70mgm 2 on day 1,
bleomycin 10mg on day 1 and
bleomycin 12mgm 2 on days 1–4 by
continuous infusion, every 3 weeks.
Bleomycin omitted after 3 cycles.
Maximum total of 6 cycles.
69 9 15 15
Abbreviations: CMF¼ cyclophosphamide, methotrexate and 5FU; CR¼ complete response; DB¼Downs and Blacks; G¼gemcitabine; GC¼gemcitabine and cisplatin; G-CSF¼granulocyte
colony-stimulating factor; MLD¼measurable locoregional disease; MMD¼measurable metastatic disease; NA¼ not available; PD¼progressive disease; PR¼partial response; VALD¼ very
advanced local disease.







First-line combination mPFS 8.4 (6.9–9.8) 0  007 0.48 (0.41–0.56) o0.0001
First-line single agent 3.5 (1.1–5.9)
First-line combination mOS 17.8 (14.2–21.4) 0  020 1.16 (0.98–1.38) 0.084
First-line single agent 8.2 (0.0–16.7)
Abbreviations: HR¼ hazard ratio; mOS¼median overall survival; mPFS¼median progression-free survival.
Table 2b. Response rate analyses for use of combination vs single agent regimens in the first-line settings











61.8 (53.5–70.1) o0.001 63.5 61.8 (54.6–69.1) o0.001
First-line single
agent
26.8 (14.2–39.4) 24.3 26.8 (22.2–61.4)
Abbreviation: ORR¼overall response rate.
Table 3a. Survival analyses for use of platinum-based vs non-platinum based regimens in the first line settings



















Abbreviations: HR¼ hazard ratio; mOS¼median overall survival; mPFS¼median progression-free survival.
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random intercept model was used in model B (Raudenbush and
Bryk, 2002).
Fisher’s Exact test was used to examine the difference in rates of
occurrence of grades 3 and 4 haematological toxicities of the
treatment regimens. Spearman correlation was used to analyse the
relationship between study outcomes (ORR, PFS and OS) and the
region where it was conducted, number of patients involved, study
DB score and the year the trial was conducted.
All analyses were conducted in SAS (version 9  4, Cary, NC,
USA). P-values of o0  05 were considered statistically significant.
Role of the funding source. There is no specific funding source
for this study.
RESULTS
Systematic search. Systematic search results are summarised in
Figure 1. A total of 56 articles were included in the final analysis of
this review (summarised in Table 1).
Assessment of study quality. All 56 studies were included in
model A analysis and 26 trials had analysable KM curves for
inclusion in model B. The mean DB score for all studies was 15.3
(range 8–25). The 26 studies included in model B analysis had
significantly higher mean DB scores than the other 30 studies (17.3
(95% CI 15.5–19.0) vs 13.7 (95% CI 12.2–15.1), P¼ 0.002).
Survival analyses. For RM-NPC patients undergoing systemic
therapy (chemotherapy and molecularly targeted agents) in the
first-line setting, the estimated median OS by model A was 15.7
months (95% CI, 12.3–19.1), while model B estimated this at 19.3
months (95% CI, 17.6–21.1). For patients undergoing second line
or higher therapies (2ndþ ), the estimated median OS by model A
was 11.5 months (95% CI 10.1–12.9), while model B estimated this
at 12.5 months (95% CI 11.9–13.4). Aggregate KM curves for OS
from model B analysis are presented in the Supplementary
Appendix Figures S1 and S2. PFS estimates for patients undergoing
first-line chemotherapy by model A was 7.6 months (95% CI,
6.2–9.0), while model B estimated this at 8.0 months (95% CI, 7.6–
8.8). For patients undergoing therapy in the 2ndþ setting, the
estimated PFS by model A was 5.4 months (95% CI, 3.8–7.0),
which was closely approximated by the model B analysis at 5.2
months (95% CI, 4.7–5.6). Aggregate KM curves for PFS from
model B analysis are presented in the Supplementary Appendix
Figures S3 and S4.
Combination chemotherapy regimens. The use of combination
therapy in the first-line setting produced a statistically significant
PFS improvement over single agent using both statistical models.
Estimated PFS by model A was 8.4 months (95% CI, 6.9–9.8) for
patients treated with combination therapy regimens in the first line
setting, in comparison to 3.5 months (95% CI, 1.1–5.9, P¼ 0.007)
for monotherapy. Hazard ratio is estimated at 0.48 (95% CI 0.41–
0.56, P¼o0.0001) using model B analysis, in favor of combina-
tion therapy regimens. The OS outcomes were different between
the two models as outlined in Table 2a and 2b. Model A showed a
statistically significant improvement with use of combination
therapy, but this was not corroborated in model B analysis.
Studies using combination chemotherapy regimens were more
likely to report the occurrence of grades 3 and 4 haematological
toxicities affecting at least 25% of all the patients enrolled in the
study (56.7 vs 9.1%, P¼ 0.011). Fifteen studies were excluded from
this analysis due to missing toxicity reporting.
Platinum-containing regimens. Model A analysis supported the
use of combination platinum-containing regimens in the first line
setting with an estimated PFS of 8.3 months (95% CI, 7.0–9.6), in
comparison to 3.5 months for non-platinum-containing therapies
(95% CI, 1.1–5  9, P¼ 0.007). Hazard ratio for the two treatment
strategies was estimated at 0.48 by model B analysis (95% CI, 0.41–
0.56, P¼o0.0001), in favor of the platinum-containing regimens.
The two statistical models again differed in their OS analyses,
where model A showed statistically significant improvement with
the use of first-line platinum-containing chemotherapy over non-
platinum regimens, while the difference was not significant for
model B. Statistical results and study distributions are summarised
in Table 3a and b.
Studies using platinum-containing regimens are more likely to
report the occurrence of grades 3 and 4 haematological toxicities
affecting at least 25% of all the patients enrolled in the study
(55.2 vs 12.5%, P¼ 0.010). Eleven studies were excluded from this
analysis due to missing toxicity reporting.
Response rate analysis. Model A analysis of mean and weighted
ORR supports the use of combination chemotherapy in the first-
line setting. The improvement in ORR with the use of platinum-
based regimens for treatment-naive patients; however, was not
found to be statistically significant when comparing to non-
platinum based regimens (Tables 2a, b and 3a, b). ORR estimations
by model B further supported the results from model A.
Use of targeted agents. Four clinical trials investigating three
molecularly targeted agents (MTAs) were identified in this
systematic review. MTAs investigated include pazopanib, gefitinib
and cetuximab (Chan et al, 2005; Chua et al, 2008; Ma et al, 2008;
Lim et al, 2011). One of the studies investigated cetuximab in
Table 3b. Response rate analyses for use of platinum-based vs non-platinum based regimens in the first line settings










First-line platinum 59.5 (50.5–68.6) 0.122 59.5 59.5 (50.5–68.5) 0.354
First-line non-
platinum
41.8 (0.0–83.6) 31.7 41.8 (22.2–61.4)
Abbreviation: ORR¼overall response rate.
Table 4. Spearman correlation coefficients
Outcome under analysis Year of publication Number of patients enrolled DB score
ORR 0.05 0.18  0.04
PFS 0.04  0.08 0.03
OS 0.43 0.19 0.29
Abreviations: DB¼Downs and Blacks; ORR¼overall response rate; OS¼overall survival; PFS¼progression-free survival.
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combination with carboplatin (Chan et al, 2005), while the other
studies investigated the pazopanib and gefitinib in three separate
studies as monotherapy (Chua et al, 2008; Ma et al, 2008; Lim et al,
2011). In three of the studies that investigated MTAs in the 2ndþ
settings, the median PFS was lower than that estimated from all
studies using both models A and B analyses. With the exception of
one study investigating gefitinib, the median OS for MTAs in the
2ndþ setting was also lower than that estimated from all studies
using both models A and B analyses (Chua et al, 2008; Ma et al,
2008; Lim et al, 2011). Currently, no MTA has been approved for
treatment of RM-NPC (Lee et al, 2015).
Analysis of outcome generalisability. Wilcoxon signed-rank test
of PFS comparing studies conducted in Asian vs non-Asian
populations showed statistically significant differences in PFS, with
higher values in non-Asian populations (P¼ 0.02). However, there
was no statistically significant difference in ORR or OS outcomes
(P¼ 0.54 and P¼ 0.53, respectively).
Spearman correlation analyses did not demonstrate any
significant relationship between ORR or PFS and the year the
study was published, number of patients enrolled, or DB score.
However, there is moderate correlation between OS and the year of
publication (Spearman correlation coefficient¼ 0  43). See Table 4
for Spearman correlation coefficients.
DISCUSSION
The first randomised phase III clinical trial in RM-NPC
compared two platinum-based combination chemotherapy regi-
mens in the first-line setting (Zhang et al, 2016). The reported
PFS with gemcitabine and cisplatin (GP) was seven months
compared with 5.6 months for 5-fluorouracil and cisplatin (FP).
PFS outcome from the superior GP regimen is comparable to the
aggregate PFS presented in our systematic review (7.6 months by
model A, and 8 months by model B analyses). Compared to the
aggregate OS however (15.7 months by model A, and 19.3
months by model B analyses), the reported median OS from the
phase III clinical trial is higher at 29.1 months and 20.9 months
for the GP and FP patient cohort, respectively (Zhang et al,
2016). Factors that may account for this difference in OS
outcomes include differences in the characteristics of the patient
population under study, better supportive or palliative care,
improved management of chemotherapy-related side effects, as
well as opportunities for patients to receive subsequent treatment
on clinical trials. In addition, the earlier identification of
progression with improved medical imaging techniques may
further introduce lead time bias for OS.
However, this phase III trial does not address whether
combination treatment is more effective than single agent therapy,
or if platinum-containing regimens are superior to non-platinum-
containing schedules. Our systematic review addressed this gap in
knowledge. Our analyses support the use of platinum combination
regimens in the first line setting with demonstrated superior PFS
and OS outcomes of combination regimens over monotherapy; and
platinum treatments over non-platinum regimens. First line
platinum combinations for treatment of patients with RM-NPC
is also recommended by expert consensus opinions such as the
National Comprehensive Cancer Network (NCCN) guideline
(Network, NCC, 2016).
Beyond the first line setting there is no standard of care
regimen; however, if patients are suitable for further treatment they
either receive another chemotherapy option such as docetaxel or
participate in a clinical trial (Network, NCC, 2016). This review
now provides important benchmarks (OS 11.5 12.5 months; PFS
5.2 5.4 months) for patients receiving second line treatment,
which can inform future clinical trials of systemic therapies in
RM-NPC. This information will be especially useful for studies
adopting a single-arm design because there is now a robust
historical control for comparison.
To our knowledge this is the first review of its kind in RM-NPC.
Furthermore, the results can be interpreted as reliable given that
the two different models typically produced similar estimates. The
reason for the discrepancy between the two models for OS
estimates for both platinum vs non-platinum regimens and
combination vs monotherapy treatments, is probably attributable
to the fewer studies included in model B because there are less
publications reporting KaplanMeier survival curves in an
extractable form and the low number of trials investigating non-
platinum-containing chemotherapy regimens and single-agent
chemotherapy in the treatment-naive patient population. In
addition, the significantly higher PFS rates in studies conducted
in non-Asian populations compared with Asian based studies is
likely due to non-Asian studies typically investigating combination
treatments. Notwithstanding, the broad range of included studies
would permit the application of this information to most, if not all,
populations of RM-NPC patients.
Our study has several limitations. The literature review was
conducted to March 2015, hence results from the phase III study
comparing two platinum-based combination chemotherapy regi-
mens in the first-line setting (Zhang et al, 2016) was not included
in the analysis. Original or reconstructed individual patient data
from all trials was not used to calculate the OS and PFS estimates.
Thus the analysis is impacted by the quality of reporting of the trial
information. Trials that did not have KM curves of sufficient image
quality could not be used, and thus reduced the number of studies
included which as result increased the variance around the
estimates. The heterogeneity of included patients in the recon-
struction of survival data using model B analysis may limit the
robustness of the results. Differences in DB scores further highlight
the heterogeneity of clinical trials design and reporting. Further-
more, given that NPC is endemic in Asia, the exclusion of studies
not published in the English language may be another limitation.
Hence the results of this review must be interpreted within that
context. It is important to note that the analyses performed in this
systematic review were not designed to identify the optimal
chemotherapy regimen, which remains to be defined. We have
been particularly careful not to report the superiority of one
specific regimen.
Interestingly our analysis demonstrated no significant changes
in ORR or PFS over time, although there is moderate correlation
between OS and the year of study publication. However, this result
needs to be interpreted with caution due to the potential for biases
given the majority of studies are single-armed with low patient
numbers, and supportive care practices may have changed over
time.
Ongoing challenges facing the interpretation of clinical
trials investigating systemic therapies in RM-NPC include diversity
in the patient demographics enrolled in the trials, lack of
standardised treatment regimens, and relatively small patient
populations studied (Zhang et al, 2016). A number of randomised
clinical trials are presently ongoing (Butte et al, 2007; Lutzky et al,
2014; Ng et al, 2016), the results of which are eagerly awaited to
resolve treatment dilemmas with generalisable result to various
patient populations. It is hoped that novel agents such as
immunotherapies may provide meaningful PFS and OS improve-
ments in future.
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